Straits Times Index
3,292.73 +2.24 (+0.07%) S&P 500
4,064.60 -15.51 (-0.38%) Dow
34,219.70 -370.07 (-1.07%) Nasdaq
11,448.83 -19.16 (-0.17%) BTC-USD
16,969.42 +92.78 (+0.55%) CMC Crypto 200
401.95 -4.20 (-1.03%)
Organon & Co. (OGN)
| Previous close | 26.02 |
| Open | 26.19 |
| Bid | 26.52 x 1000 |
| Ask | 26.54 x 1800 |
| Day's range | 26.11 - 26.85 |
| 52-week range | 22.88 - 39.47 |
| Volume | |
| Avg. volume | 1,980,980 |
| Market cap | 6.702B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 6.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.12 (4.54%) |
| Ex-dividend date | 10 Nov 2022 |
| 1y target est | N/A |
- Business Wire
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
JERSEY CITY, N.J., November 15, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.
- CNW Group
Organon Canada launches Ontruzant®, a biosimilar of the reference biologic Herceptin®, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost
Organon (NYSE: OGN), a global women's health company, today announced the availability and distribution of Ontruzant®, a biosimilar of Herceptin®, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC).1
- CNW Group
Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer
Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recur
